Table 1.
Main characteristics of included studies.
| Study | Sample size | Diagnostic criteria of PSD | Baseline HAMD | Intervention | Control | No. of EA sessions | Treatment duration | Jadad score |
|---|---|---|---|---|---|---|---|---|
| Zhang and Yan [8] | E: 35 C: 35 |
CCMD/HAMD | E: 20.97 ± 4.16 C: 22.97 ± 5.77 |
GV20, HT7, LR3; 30 min, once a day | 20 mg/d paroxetine | 28 | 4 | 2 (2, 0, 0, 0) |
| Xu and Miago [7] | E: 40 C: 40 |
CCCD/CCMD/HAMD | E: 30.96 ± 4.25 C: 30.65 ± 3.98 |
GV20, EX-HN1, EX-HN3, LR3, HT7, PC6, KI3, SP6, BL15; 30 min, once a day | 20 mg/d fluoxetine | 42 | 6 | 1 (1, 0, 0, 0) |
| Wang et al. [6] | E: 25 E2: 25 E3: 25 C: 25 |
CCCD/CCMD/HAMD | E1: 22.35 ± 2.48 E2: 22.20 ± 1.97 E3: 21.97 ± 2.35 C: 21.38 ± 2.46 |
GV20, GV24, PC6, HT7; 30 min, once a day | 50 mg/d sertraline | 30 | 4 | 2 (1, 1, 0, 0) |
| Li et al. [19] | E: 11 C: 10 |
CCCD/HAMD | E: 31.2 ± 3.91 C: 30.2 ± 3.62 |
LI4, LR3; 20 min, once a day | 20 mg/d fluoxetine | 40 | 8 | 3 (2, 1, 0, 0) |
| Hong et al. [9] | E: 30 C: 30 |
CCCD/CCMD/HAMD | E: 25.45 ± 3.22 C: 24.87 ± 2.69 |
GV20, EX-HN1, GV24, ST36, LR3, SP6; 30 min, once a day | 20 mg/d citalopram | 30 | 4 | 3 (2, 1, 0, 0) |
| Kang and Yang [20] | E: 40 C: 40 |
CCCD/CCMD/HAMD | E: 36.83 ± 7.76 C: 35.17 ± 8.22 |
GV24, G13, GB31, SJ17, EX-HN3; 30 min, once a day | 20 mg/d fluoxetine | 28 | 4 | 1 (1, 0, 0, 0) |
| Huang et al. [10] | E: 30 C: 30 |
CCCD/CCMD/HAMD | E: 19.00 ± 2.55 C: 19.10 ± 2.46 |
GV20, GV18, G13 and G9; 30 min, once a day | 20 mg/d fluoxetine | 30 | 6 | 3 (2, 1, 0, 0) |
| Li et al. [21] | E: 35 C: 35 |
CCCD/CCMD/HAMD | E: 32.40 ± 3.92 C: 31.60 ± 4.37 |
EX-HN1, GV24, G13, LI4, LR3; 30 min, once a day | 20 mg/d fluoxetine | 28 | 4 | 1 (1, 0, 0, 0) |
| Zhu et al. [22] | E: 32 C: 30 |
CCCD/CCMD/HAMD | E: 26.20 ± 3.67 C: 27.10 ± 3.02 |
LI4, LR3; 20 min, once a day | 20 mg/d fluoxetine | 40 | 8 | 1 (1, 0, 0, 0) |
| Chen [11] | E: 47 C: 47 |
CCCD/CCMD/HAMD | E: 23.59 ± 4.04 C: 23.45 ± 3.69 |
GV20, EX-HN1, ST8, GB8, HT7; 30 min, once a day | 20 mg/d fluoxetine | 36 | 12 | 3 (2, 1, 0, 0) |
| Peng et al. [23] | E: 58 C: 59 |
CCCD/CCMD/HAMD | E: 30.19 ± 2.22 C: 29.87 ± 2.76 |
Nie San Zheng, PC6, ST36, LR3, ST40; 20 min, once a day | 20 mg/d fluoxetine | 24 | 4 | 3 (2, 1, 0, 0) |
| Guo et al. [12] | E: 32 C: 31 |
CCCD/CCMD/HAMD | E: 21.74 ± 5.50 C: 21.08 ± 5.72 |
GV20, EX-HN1, GV24, EX-HN3, LI4, LR3; 30 min, once a day | 20 mg/d fluoxetine | 30 | 6 | 1 (1, 0, 0, 0) |
| Zhou et al. [13] | E: 145 C:148 |
CCCD/CCMD/HAMD | E: 31.84 ± 13.12 C: 32.28 ± 12.57 |
GV20, EX-HN3, GV24, GV26, LI4, PC6, SP6, ST36, LR3; 30 min, once a day | 20 mg/d fluoxetine | 45 | 8 | 2 (2, 0, 0, 0) |
| Bi et al. [15] | E: 31 C: 32 |
CCCD/HAMD | E: 22.42 ± 2.93 C: 22.16 ± 2.16 |
GV20, EX-HN3; 45 min, once a day | 20 mg/d fluoxetine | 30 | 6 | 2 (2, 0, 0, 0) |
| Zhou [14] | E: 32 C: 34 |
CCCD/HAMD | E: 23.71 ± 9.36 C: 23.02 ± 10.47 |
GV20, EX-HN3; 45 min, once a day | 20 mg/d fluoxetine | 28 | 4 | 1 (1, 0, 0, 0) |
| Dong et al. [24] | E: 74 C: 34 |
CCCD/CCMD/HAMD | E: 24.67 ± 2.59 C: 24.12 ± 3.17 |
GV24, GV17, GB5, GB6, GV18, GB15, GB8, GB7, EX-HN3; 30 min, once a day | 20 mg/d fluoxetine | 30 | 4 | 2 (2, 0, 0, 0) |
| Chu et al. [16] | E: 36 C: 36 |
CCCD/CCMD/HAMD | E: 22.38 ± 5.87 C: 23.42 ± 6.12 |
GV20, EX-HN3, GV26, PC6; 30 min, once a day | 20 mg/d fluoxetine | 40 | 8 | 2 (2, 0, 0, 0) |
| Chen et al. [17] | E: 30 C: 30 |
CCCD/CCMD/HAMD | E: 29.34 ± 3.60 C: 31.05 ± 5.30 |
GV20, GV24, EX-HN1, EX-HN3, HT7, PC6, LR3; 20 min, once a day |
20 mg/d fluoxetine | 20 | 4 | 2 (2, 0, 0, 0) |
| Long et al. [18] | E: 36 C: 36 |
CCCD/HAMD | E: 22.30 ± 5.70 C: 22.70 ± 5.20 |
GV20, EX-HN3; 45 min, once a day | 10-40 mg/d fluoxetine | 24 | 4 | 1 (1, 0, 0, 0) |